+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Selzentry"

HIV Drugs Market Analysis & Forecast to 2024-2034 - Product Thumbnail Image

HIV Drugs Market Analysis & Forecast to 2024-2034

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Selzentry - API Insight, 2022 - Product Thumbnail Image

Selzentry - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
HIV Drugs Market By Medication Class, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2023-2032 - Product Thumbnail Image

HIV Drugs Market By Medication Class, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2023-2032

  • Report
  • November 2023
  • 35 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Selzentry (maraviroc) is a prescription medication used to treat HIV/AIDS. It is a CCR5 antagonist, meaning it blocks the CCR5 receptor on the surface of certain immune cells, preventing HIV from entering and infecting them. Selzentry is used in combination with other antiretroviral medications to treat HIV-1 infection in adults and children over the age of two. It is also used to reduce the risk of HIV-1 infection in adults who are at high risk of becoming infected. Selzentry is manufactured by ViiV Healthcare, a joint venture between GlaxoSmithKline, Pfizer, and Shionogi. Other companies in the market include Gilead Sciences, Merck, and Bristol-Myers Squibb. Show Less Read more